✦ LIBER ✦

224 oral Interface dosimetry of lung and chest wall in the radiation treatment of breast cancer

Book ID: 119511591
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 150 KB
Volume: 58
Category: Article
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(01)80365-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Surgical treatment of lung cancer invadi

Surgical treatment of lung cancer invading the chest wall: results and prognostic factors

✍ Pierre Magdeleinat; Marco Alifano; Cedrik Benbrahem; Lorenzo Spaggiari; Calogero 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 224 KB

Stereotactic Body Radiation Therapy for

Stereotactic Body Radiation Therapy for Early Stage Lung Cancer: Quantifying the Effect of Tracking With Respiratory Motion on Chest Wall Dosimetry

✍ Goldin, G.H.; Carter, J.; Zagar, T.; Fayda, M.; Prasad, S.; Fakiris, A.; Chen, R 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Superficial microwave-induced hypertherm

Superficial microwave-induced hyperthermia in the treatment of chest wall recurrences in breast cancer

✍ J. B. Dubois; M. Hay; G. Bordure 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

Irradiation of the Chest Wall and Region

Irradiation of the Chest Wall and Regional Nodes as Integrated Volume With IMRT for Breast Cancer: The Dosimetry and Acute Side Effects

✍ Ma, J.; Li, J.; Chen, J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Evaluating Stereotactic Body Radiotherap

Evaluating Stereotactic Body Radiotherapy with Protons to Reduce Chest Wall Dose in the Treatment of Lung Cancer

✍ K.T. Ciura; J. Welsh; N. Nguyen; M. Palmer; M. Paolini; J. Bluett; R. Mohan; D. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 36 KB

Oral medroxyprogesterone in the treatmen

Oral medroxyprogesterone in the treatment of metastatic breast cancer

✍ Takuma Nemoto; Jashbha1 Patel; Dutzu Rosner; Thomas L. Dao 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

In 47 postmenopausal women with evaluable breast cancer, oral medroxyprogesterone acetate (MPA) was given at a daily dose level of 400 mg. Patients with negative estrogen receptors, poor performance status , or nonresponse to previous endocrine therapy were excluded from this study. There were 25 (